Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3511 - Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer


08 Oct 2016


Poster Display


Cristiana Lo Nigro


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


C. Lo Nigro1, A. Comino2, D. Vivenza1, C. Granetto1, M. Ferrero3, L. Lattanzio1, C. Varamo1, V. Ricci1, M.C. Merlano1

Author affiliations

  • 1 Clinical Oncology, S. Croce Teaching Hospital, 12100 - Cuneo/IT
  • 2 Pathology, S. Croce Teaching Hospital, 12100 - Cuneo/IT
  • 3 Pathology, Oncology, S. Croce Teaching Hospital, 12100 - Cuneo/IT


Abstract 3511


TNM, stage and key biological markers direct the choice of adjuvant chemotherapy. Stage II colon cancer (CC) is a heterogeneous disease with different clinical behavior. For this reason there is a high degree of uncertainty in recommending adjuvant chemotherapy. Pathological features are routinely employed to distinguish high and low risk stage II disease. Adjuvant chemotherapy is usually suggested in the high-risk population. Published data suggest that specific tumor-infiltrating lymphocytes (S-TILs) (CD3 + , CD8 + , CD45RO+) may represent a valuable prognostic tool to drive the decision-making process.


We performed an analysis on 49 cases of CC patients underwent to adjuvant therapy, of which 34 relapsed and 15 did not. We analyzed the density of CD3 + , CD8+ and CD45RO+ (memory cells) in the surgical samples after radical surgery by IHC in the center of the tumor (CT) and in its invasive margin (IM). Measurements were recorded by image analysis as the number of positive cells per tissue surface unit in square millimeters. For each marker, we identified two grading of staining, high density (HD) or low density (LD), where the cut-off was the median value observed. DFS and OS between HD and LD were compared by Log Rank test. This analysis was conducted to stratify patients in two cohorts: stage II (26 pts) and stage III (23 pts).


We limit the present report to the cumulative analysis of each cohort. In CT, HD CD3+ affects OS (p = 0.034) and HD CD45RO+ affects DFS(p = 0.002) in stage II pts. We did not observed any impact in OS nor in DFS for stage III pts. In IM, no correlation was found with OS, both in stage II and III pts, while for DFS HD CD3 + , CD8+ and CD45RO+ showed significant benefit compared to LD (p = 0.016, p = 0.0095 and p = 0.0014 respectively) only in stage II pts.


S-TILs (CD3 + , CD8 + , CD45RO+) might represent a valuable prognostic tool to drive the decision-making process especially for stage II CC disease. All these observations suggest a more pronounced role of S-TILs in IM compared to CT. Our results will be verified in ongoing large prospective study.

Clinical trial identification

Legal entity responsible for the study

M.C. Merlano


ARCO Foundation


M.C. Merlano: Consultant for Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings